Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification

Fibroblast growth factor receptor 2 (FGFR2) amplification has been reported in 5-10% of gastric cancer (GC) and is associated with poor prognosis. In this study, we characterized the anti-tumor effect of PRO-007, a newly developed recombinant monoclonal antibody that targets FGFR2, in GC cell lines...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Am J Transl Res
Auteurs principaux: Kim, Seung Tae, Lee, In Kyoung, Rom, Eran, Sirkis, Roy, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Kim, Kyoung-Mee, Yayon, Avner, Lee, Jeeyun
Format: Artigo
Langue:Inglês
Publié: e-Century Publishing Corporation 2019
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6684926/
https://ncbi.nlm.nih.gov/pubmed/31396354
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires